A rituximab-based therapy regimen successfully treated a 16-year-old girl with primary cold agglutinin disease (CAD), according to researchers in the U.S. who say the case represents “the youngest patient reported with this diagnosis.” The case study, “An unusual case of primary cold agglutinin-associated lymphoproliferative disease…
Read more
I was doing my best not to panic. I couldn’t get away even if I tried — there were too many assistant vampires surrounding me, and I couldn’t overpower them all. My breath came in short gasps, and I grew dizzy. Ouchie-wow-wow! Oh, that hurt. Over and over, the vicious…
Long-term treatment with Enjaymo (sutimlimab-jome) in people with cold agglutinin disease (CAD) results in rapid and sustained reductions in red blood cell destruction and anemia, as well as clinically-meaningful reductions in fatigue. That’s according to 2.5 years of data from the Phase 3 CARDINAL clinical trial, which tested…
Way back in the early 1990s, when we were preparing to live in a tropical rainforest, a wonderful book was recommended to us called the “Village Medical Manual.” It was a compendium of diseases and symptoms and gave the reader a smorgasbord of ailments from which…
Columnist Mary Lott shares how attending the funeral of a loved one came with a heavy price: a lengthy recurrence of her CAD symptoms.
Check out Cold Agglutinin Disease News‘ collection of health insights, where you can find more information and guidance.
Click the link below to go to our FAQs page on cold agglutinin disease.
Cold agglutinin disease (CAD) is a rare disorder in which the immune system mistakenly attacks red blood cells, resulting in anemia.
CAD is characterized by autoantibodies, called cold agglutinins, binding to and activating the destruction of red blood cells when exposed to cold temperatures.
Symptoms of CAD include fatigue, Raynaud’s syndrome, joint pain, jaundice or skin discoloration, and heart problems. These symptoms can worsen with more cold exposure.
Get regular updates to your inbox.